• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The use of modeling tools to drive efficient oral product design.利用建模工具提高口腔产品设计效率。
AAPS J. 2012 Sep;14(3):591-600. doi: 10.1208/s12248-012-9372-3. Epub 2012 May 30.
2
In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.在药物产品开发中的胃肠道药物吸收的计算预测:机制吸收模型 GI-Sim 的应用。
Eur J Pharm Sci. 2013 Jul 16;49(4):679-98. doi: 10.1016/j.ejps.2013.05.019. Epub 2013 May 29.
3
Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis.利用 pH 调节剂改善具有 pH 依赖性溶解度的药物的溶出行为和口服吸收:一种生理现实的质量传递分析。
Mol Pharm. 2021 Sep 6;18(9):3326-3341. doi: 10.1021/acs.molpharmaceut.1c00262. Epub 2021 Aug 24.
4
Mechanistic Oral Absorption Modeling and Simulation for Formulation Development and Bioequivalence Evaluation: Report of an FDA Public Workshop.用于制剂开发和生物等效性评估的机制性口服吸收建模与模拟:美国食品药品监督管理局公开研讨会报告
CPT Pharmacometrics Syst Pharmacol. 2017 Aug;6(8):492-495. doi: 10.1002/psp4.12204. Epub 2017 Jul 11.
5
Applications of bio-predictive dissolution tools for the development of solid oral dosage forms: current industry experience.生物预测性溶出工具在固体口服制剂研发中的应用:行业现状
Drug Dev Ind Pharm. 2022 Mar;48(3):79-97. doi: 10.1080/03639045.2022.2098315. Epub 2022 Jul 13.
6
PBPK models for the prediction of in vivo performance of oral dosage forms.用于预测口服剂型体内性能的生理药代动力学(PBPK)模型。
Eur J Pharm Sci. 2014 Jun 16;57:300-21. doi: 10.1016/j.ejps.2013.09.008. Epub 2013 Sep 21.
7
Use of Gastrointestinal Simulator, Mass Transport Analysis, and Absorption Simulation to Investigate the Impact of pH Modifiers in Mitigating Weakly Basic Drugs' Performance Issues Related to Gastric pH: Palbociclib Case Study.使用胃肠道模拟器、传质分析和吸收模拟来研究pH调节剂对缓解弱碱性药物与胃pH值相关性能问题的影响:帕博西尼案例研究。
Mol Pharm. 2023 Jan 2;20(1):147-158. doi: 10.1021/acs.molpharmaceut.2c00545. Epub 2022 Nov 11.
8
The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.生物药剂学分类系统:体内预测溶出度(IPD)方法和体外-体内相关性的子类。
Eur J Pharm Sci. 2014 Jun 16;57:152-63. doi: 10.1016/j.ejps.2014.01.009. Epub 2014 Jan 28.
9
Drug dissolution and transit in a heterogenous gastric chyme after fed administration: Semi-mechanistic modeling and simulations for an immediate-release and orodispersible tablets containing a poorly soluble drug.经口给药后异质胃食糜中的药物溶出和转运:含难溶性药物的即释和口腔分散片的半机械建模与模拟。
Eur J Pharm Biopharm. 2024 Jul;200:114341. doi: 10.1016/j.ejpb.2024.114341. Epub 2024 May 23.
10
Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.基于模型的生物药剂学实验分析,以改善机制口服吸收建模:以酮康唑为模型药物的体外-体内外推综合视角。
Mol Pharm. 2017 Dec 4;14(12):4305-4320. doi: 10.1021/acs.molpharmaceut.7b00406. Epub 2017 Aug 25.

引用本文的文献

1
Model-Informed Drug Development: In Silico Assessment of Drug Bioperformance following Oral and Percutaneous Administration.模型指导的药物研发:口服和经皮给药后药物生物性能的计算机模拟评估
Pharmaceuticals (Basel). 2024 Jan 30;17(2):177. doi: 10.3390/ph17020177.
2
Combined Methodologies for Determining Bioavailability of Drugs and Prediction of Bioequivalence From Pharmaceutical Oral Formulations.用于测定药物生物利用度及预测药物口服制剂生物等效性的联合方法
Front Chem. 2021 Nov 3;9:741876. doi: 10.3389/fchem.2021.741876. eCollection 2021.
3
Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products.综合多方利益相关者系统思维策略:使用生物药剂学风险评估路线图(BioRAM)进行决策,优化药物产品的临床性能。
AAPS J. 2020 Jul 27;22(5):97. doi: 10.1208/s12248-020-00470-z.
4
Utilization of In Vitro, In Vivo and In Silico Tools to Evaluate the pH-Dependent Absorption of a BCS Class II Compound and Identify a pH-Effect Mitigating Strategy.利用体外、体内和计算工具评估 BCS Ⅱ类化合物的 pH 依赖性吸收并确定 pH 效应缓解策略。
Pharm Res. 2019 Oct 21;36(12):164. doi: 10.1007/s11095-019-2698-0.
5
Mechanistic prediction of food effects for Compound A tablet using PBPK model.使用生理药代动力学(PBPK)模型对化合物A片剂的食物效应进行机制预测。
Saudi J Biol Sci. 2017 Mar;24(3):603-609. doi: 10.1016/j.sjbs.2017.01.032. Epub 2017 Feb 11.
6
Characterising Drug Release from Immediate-Release Formulations of a Poorly Soluble Compound, Basmisanil, Through Absorption Modelling and Dissolution Testing.通过吸收建模和溶出度测试对难溶性化合物巴斯米尼尔速释制剂的药物释放特性进行表征。
AAPS J. 2017 May;19(3):827-836. doi: 10.1208/s12248-017-0060-1. Epub 2017 Feb 24.
7
Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.基于生理的药代动力学模型:实现个性化医疗的方法。
J Pharmacokinet Pharmacodyn. 2016 Oct;43(5):481-504. doi: 10.1007/s10928-016-9492-y. Epub 2016 Sep 19.
8
Quantitative Systems Pharmacology: A Framework for Context.定量系统药理学:一种情境框架。
Curr Pharmacol Rep. 2016 Jun;2(3):152-160. doi: 10.1007/s40495-016-0058-x. Epub 2016 Apr 8.
9
Lipid-associated oral delivery: Mechanisms and analysis of oral absorption enhancement.脂质相关的口服给药:口服吸收增强的机制与分析
J Control Release. 2016 Oct 28;240:544-560. doi: 10.1016/j.jconrel.2016.07.050. Epub 2016 Aug 9.
10
Physiologically Based Absorption Modeling to Design Extended-Release Clinical Products for an Ester Prodrug.基于生理的吸收建模,用于设计酯前药的缓释临床产品。
AAPS J. 2016 Nov;18(6):1424-1438. doi: 10.1208/s12248-016-9950-x. Epub 2016 Jul 12.

本文引用的文献

1
Biowaiver approach for biopharmaceutics classification system class 3 compound metformin hydrochloride using in silico modeling.采用体内外相关性研究法对生物药剂学分类系统第 3 类化合物盐酸二甲双胍进行生物豁免研究。
J Pharm Sci. 2012 May;101(5):1773-82. doi: 10.1002/jps.23063. Epub 2012 Feb 14.
2
Predicting orally disintegrating tablets formulations of ibuprophen tablets: an application of the new SeDeM-ODT expert system.预测布洛芬片剂的口腔崩解片制剂:新 SeDeM-ODT 专家系统的应用。
Eur J Pharm Biopharm. 2012 Apr;80(3):638-48. doi: 10.1016/j.ejpb.2011.12.012. Epub 2012 Jan 5.
3
Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies.IVIVE 和 PBPK 模型在临床药代动力学前瞻性预测中的应用:药物发现阶段的策略和方法,附四个案例研究。
Biopharm Drug Dispos. 2012 Mar;33(2):85-98. doi: 10.1002/bdd.1769. Epub 2012 Jan 24.
4
Using absorption simulation and gastric pH modulated dog model for formulation development to overcome achlorhydria effect.采用吸收模拟和胃 pH 调节犬模型进行制剂开发以克服胃酸缺乏效应。
Mol Pharm. 2011 Dec 5;8(6):2216-23. doi: 10.1021/mp200062a. Epub 2011 Oct 20.
5
An update on computational oral absorption simulation.计算口腔吸收模拟的最新进展。
Expert Opin Drug Metab Toxicol. 2011 Nov;7(11):1345-64. doi: 10.1517/17425255.2011.617743. Epub 2011 Sep 23.
6
Effect of gastric pH on the pharmacokinetics of a BCS class II compound in dogs: utilization of an artificial stomach and duodenum dissolution model and GastroPlus,™ simulations to predict absorption.胃 pH 值对犬体内 BCS Ⅱ类化合物药代动力学的影响:利用人工胃和十二指肠溶解模型以及 GastroPlus™模拟预测吸收。
J Pharm Sci. 2011 Nov;100(11):4756-65. doi: 10.1002/jps.22669. Epub 2011 Jun 16.
7
Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling.应用基于生理学的药代动力学模型模拟 21 种不同化合物的人体静脉内和口服药代动力学。
Clin Pharmacokinet. 2011 May;50(5):331-47. doi: 10.2165/11539680-000000000-00000.
8
Utility of physiologically based absorption modeling in implementing Quality by Design in drug development.生理基础吸收模型在药物开发中实施质量源于设计的应用
AAPS J. 2011 Mar;13(1):59-71. doi: 10.1208/s12248-010-9250-9. Epub 2011 Jan 5.
9
Physiologically-based pharmacokinetics in drug development and regulatory science.生理药代动力学在药物研发和监管科学中的应用。
Annu Rev Pharmacol Toxicol. 2011;51:45-73. doi: 10.1146/annurev-pharmtox-010510-100540.
10
A pH-dilution method for estimation of biorelevant drug solubility along the gastrointestinal tract: application to physiologically based pharmacokinetic modeling.一种用于估计胃肠道生物相关药物溶解度的 pH 稀释法:在基于生理的药代动力学建模中的应用。
Mol Pharm. 2010 Oct 4;7(5):1516-26. doi: 10.1021/mp100157s. Epub 2010 Aug 17.

利用建模工具提高口腔产品设计效率。

The use of modeling tools to drive efficient oral product design.

机构信息

Drug Product Science & Technology Department, Bristol-Myers Squibb Co, New Brunswick, New Jersey 08903, USA.

出版信息

AAPS J. 2012 Sep;14(3):591-600. doi: 10.1208/s12248-012-9372-3. Epub 2012 May 30.

DOI:10.1208/s12248-012-9372-3
PMID:22644702
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3385810/
Abstract

Modeling and simulation of drug dissolution and oral absorption has been increasingly used over the last decade to understand drug behavior in vivo based on the physicochemical properties of Active Pharmaceutical Ingredients (API) and dosage forms. As in silico and in vitro tools become more sophisticated and our knowledge of physiological processes has grown, model simulations can provide a valuable confluence, tying-in in vitro data with in vivo data while offering mechanistic insights into clinical performance. To a formulation scientist, this unveils not just the parameters that are predicted to significantly impact dissolution/absorption, but helps probe explanations around drug product performance and address specific in vivo mechanisms. In formulation, development, in silico dissolution-absorption modeling can be effectively used to guide: API selection (form comparison and particle size properties), influence clinical study design, assess dosage form performance, guide strategy for dosage form design, and breakdown clinically relevant conditions on dosage form performance (pH effect for patients on pH-elevating treatments, and food effect). This minireview describes examples of these applications in guiding product development including those with strategies to mitigate observed clinical exposure liability or mechanistically probe product in vivo performance attributes.

摘要

在过去十年中,基于活性药物成分 (API) 和剂型的物理化学性质,药物溶解和口服吸收的建模和模拟越来越多地用于了解体内药物行为。随着计算和体外工具变得更加复杂,我们对生理过程的了解也不断增加,模型模拟可以提供有价值的融合,将体外数据与体内数据联系起来,同时为临床性能提供机制见解。对于制剂科学家来说,这不仅揭示了预计会显著影响溶解/吸收的参数,还有助于探究药物产品性能的解释,并解决特定的体内机制问题。在制剂开发中,计算溶解-吸收模型可以有效地用于指导:API 选择(剂型比较和粒径特性)、影响临床研究设计、评估剂型性能、指导剂型设计策略以及分解剂型性能的临床相关条件(对接受升高 pH 治疗的患者的 pH 影响,以及食物影响)。这篇综述性文章介绍了这些应用在指导产品开发方面的示例,包括那些具有减轻观察到的临床暴露风险或从机制上探究产品体内性能属性的策略。